HEMANGEOL

LOE Approaching

propranolol hydrochloride

Pierre Fabre
NDAORALSOLUTION
Approved
Mar 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100

Mechanism of Action

HEMANGEOL's effects on infantile hemangiomas is not well understood.

Indications (1)

proliferating infantile hemangioma requiring systemic therapy

Loss of Exclusivity

LOE Date
Oct 16, 2028
31 months away
Patent Expiry
Oct 16, 2028

Patent Records (2)

Patent #ExpiryTypeUse Code
8338489
Oct 16, 2028
U-1496
8987262
Oct 16, 2028
U-1988
Company
Pierre Fabre
Pierre Fabre
France - Aignan
192 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers